Corvilain B
Service d'Endocrinologie, Hôpital Erasme, Bruxelles.
Rev Med Brux. 2012 Sep;33(4):241-5.
Subclinical hyperthyroidism is a common clinical entity. Subclinical hyperthyroidism is defined as a serum TSH below the reference range but a normal T4 and T3 level in an asymptomatic patient. Whether or not subclinical hyperthyroidism should be treated remains a matter of debate. Cross-sectional studies and longitudinal population-based studies demonstrate association between subclinical hyperthyroidism and risk of atrial fibrillation, osteoporosis and cardiovascular and global mortality. However, there are no randomized clinical trials answering the question whether long term-health outcomes are improved by the treatment of subclinical hyperthyroidism. Therefore in the absence of evidence for or against treatment of subclinical hyperthyroidism, it seems appropriate to follow algorithms that consider the level of TSH and the presence of risks factors (age > 65 years, osteoporosis, post menopause and cardiac disease).
亚临床甲状腺功能亢进是一种常见的临床病症。亚临床甲状腺功能亢进的定义为,在无症状患者中,血清促甲状腺激素(TSH)低于参考范围,但甲状腺素(T4)和三碘甲状腺原氨酸(T3)水平正常。亚临床甲状腺功能亢进是否应接受治疗仍是一个有争议的问题。横断面研究和基于人群的纵向研究表明,亚临床甲状腺功能亢进与心房颤动、骨质疏松症、心血管疾病及全因死亡率之间存在关联。然而,尚无随机临床试验来回答治疗亚临床甲状腺功能亢进是否能改善长期健康结局这一问题。因此,在缺乏支持或反对治疗亚临床甲状腺功能亢进的证据的情况下,遵循考虑TSH水平和风险因素(年龄>65岁、骨质疏松症、绝经后及心脏病)的算法似乎是合适的。